C. Comeaux

Prevention of Respiratory Syncytial Virus Infection in Healthy Adults by a Single Immunization of Ad26.RSV.preF in a Human Challenge Study

Rob Lambkin-Williams, A. Gilbert, H. Schuitemaker, 2021, The Journal of infectious diseases.

Burden of respiratory syncytial virus infection in older and high-risk adults: a systematic review and meta-analysis of the evidence from developed countries

J. Nguyen-Van-Tam, E. Martin, R. Fleischhackl, 2022, European Respiratory Review.

Efficacy and Safety of an Ad26.RSV.preF-RSV preF Protein Vaccine in Older Adults.

A. Falsey, J. Sadoff, J. Menten, 2023, The New England journal of medicine.

Safety and Immunogenicity of the Ad26.RSV.preF Investigational Vaccine Coadministered With an Influenza Vaccine in Older Adults.

H. Schuitemaker, J. Sadoff, W. Haazen, 2020, The Journal of infectious diseases.

Antibody effector functions are associated with protection from respiratory syncytial virus

D. Lauffenburger, G. Alter, L. van der Fits, 2022, Cell.

Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1/2a Study

J. Kublin, D. Montefiori, H. Schuitemaker, 2022, The Journal of infectious diseases.

Evaluation of symptoms in respiratory syncytial virus infection in adults: psychometric evaluation of the Respiratory Infection Intensity and Impact Questionnaire™ symptom scores

L. Nelson, R. Osborne, G. Ispas, 2023, Journal of Patient-Reported Outcomes.

Vaccine-induced antibody Fc-effector functions in humans immunized with a combination Ad26.RSV.preF/RSV preF protein vaccine

J. Tolboom, D. Cizmeci, Nickita Mehta, 2023, Journal of virology.